According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
A number of other analysts have also issued reports on the stock. Needham & Company LLC restated a buy rating and set a $20.00 target price on shares of Dermira in a research report on Monday, December 30th. Svb Leerink reiterated an outperform rating on shares of Dermira in a report on Thursday, January 2nd. Leerink Swann decreased their price target on shares of Dermira from $23.00 to $15.00 and set an outperform rating on the stock in a report on Tuesday, November 5th. Evercore ISI reiterated a buy rating on shares of Dermira in a report on Thursday, December 12th. Finally, BidaskClub upgraded shares of Dermira from a buy rating to a strong-buy rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $17.63.
Shares of NASDAQ DERM opened at $19.13 on Tuesday. Dermira has a 1 year low of $5.25 and a 1 year high of $19.48. The firm’s 50 day moving average price is $13.02 and its 200 day moving average price is $9.15. The firm has a market cap of $1.05 billion, a P/E ratio of -3.65 and a beta of 1.62. The company has a debt-to-equity ratio of 25.08, a quick ratio of 6.63 and a current ratio of 7.03.
Dermira (NASDAQ:DERM) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.40) by $0.34. Dermira had a negative net margin of 256.08% and a negative return on equity of 583.07%. The firm had revenue of $11.53 million for the quarter, compared to analyst estimates of $11.07 million. As a group, equities analysts predict that Dermira will post -4.21 EPS for the current year.
In other Dermira news, Director Matthew K. Fust sold 3,000 shares of Dermira stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $12.00, for a total value of $36,000.00. Following the transaction, the director now owns 8,051 shares in the company, valued at approximately $96,612. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.40% of the stock is owned by company insiders.
Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Dermira by 10.2% in the 2nd quarter. Vanguard Group Inc. now owns 2,333,482 shares of the biopharmaceutical company’s stock valued at $22,308,000 after acquiring an additional 216,449 shares during the period. California State Teachers Retirement System raised its stake in shares of Dermira by 2.6% in the 3rd quarter. California State Teachers Retirement System now owns 73,649 shares of the biopharmaceutical company’s stock valued at $471,000 after acquiring an additional 1,857 shares during the period. California Public Employees Retirement System raised its stake in shares of Dermira by 70.3% in the 3rd quarter. California Public Employees Retirement System now owns 24,119 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 9,958 shares during the period. Virtu Financial LLC purchased a new position in shares of Dermira in the 3rd quarter valued at $85,000. Finally, State Street Corp raised its stake in shares of Dermira by 2.2% in the 3rd quarter. State Street Corp now owns 942,061 shares of the biopharmaceutical company’s stock valued at $6,020,000 after acquiring an additional 20,671 shares during the period. 94.49% of the stock is currently owned by institutional investors and hedge funds.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Featured Article: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.